文献速递白血病

STAT5磷酸化联合微小残留病定义成人B细胞急性淋巴细胞白血病新型风险分类

STAT5 phosphorylation plus minimal residual disease defines a novel risk classification in adult B-cell acute lymphoblastic leukaemia.
PubMed 文献 · Br J Haematol · 2024-04-19

该前瞻性研究纳入PDT-ALL-2016队列184例成人B-ALL患者,诊断时用流式细胞术检测pSTAT5,并分为pSTAT5低表达组(113/184,61.1%)和高表达组(71/184,38.9%)。pSTAT5高表达组的总生存和无事件生存均劣于低表达组,且pSTAT5联合诱导后MRD可将患者分为高危、标危和中危三组,生存曲线差异显著。

要点

  • pSTAT5高表达组总生存44.8% vs 低表达组65.2%(p=0.004),无事件生存23.5% vs 52.1%(p<0.001)。
  • pSTAT5联合诱导后MRD定义高危(pSTAT5高+MRD+)、标危(pSTAT5低+MRD-)和中危组。
  • 三组3年总生存率分别为36.5%、56.7%和76.3%(p<0.001),多因素分析风险比3.53(p=0.003)。

核心结论

  • 整合pSTAT5和MRD的流式风险分类有助于B-ALL的风险导向治疗。

研究设计与样本

  • 前瞻性研究,纳入2018年1月至2021年12月PDT-ALL-2016队列的184例成人B-ALL患者,诊断时用流式细胞术检测STAT5磷酸化。

主要发现

  • pSTAT5高表达组(71/184,38.9%)总生存44.8% vs pSTAT5低表达组(113/184,61.1%)65.2%(p=0.004),无事件生存23.5% vs 52.1%(p<0.001)。
  • pSTAT5联合诱导后MRD定义高危(pSTAT5高+MRD+)、标危(pSTAT5低+MRD-)和中危组,三组3年总生存率分别为36.5%、56.7%和76.3%(p<0.001)。
  • 多因素分析风险比3.53(p=0.003)。

关键数值与推荐

  • pSTAT5低表达:113/184(61.1%);pSTAT5高表达:71/184(38.9%)。
  • 高危组:pSTAT5高+MRD+;标危组:pSTAT5低+MRD-;其余为中危组。
  • 三组3年总生存率:36.5%、56.7%、76.3%(p<0.001)。

临床怎么用

  • 作者提出基于流式细胞术整合pSTAT5和MRD的新型风险分类,有利于B-ALL的风险导向治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The dysregulation of the Janus family tyrosine kinase-signal transducer and activator of transcription (JAK-STAT) is closely related to acute lymphoblastic leukaemia (ALL), whereas the clinical value of phosphorylated STAT5 (pSTAT5) remains elusive. Herein we performed a prospective study on clinical significance of flow cytometry-based pSTAT5 in adult B-ALL patients. A total of 184 patients were enrolled in the Precision-Classification-Directed-Target-Total-Therapy (PDT)-ALL-2016 cohort between January 2018 and December 2021, and STAT5 phosphorylation was detected by flow cytometry at diagnosis. Based on flow-pSTAT5, the population was classified into pSTAT5low (113/184, 61.1%) and pSTAT5high (71/184, 38.9%). Overall survival (OS) and event-free survival (EFS) were inferior in pSTAT5high patients than in those with pSTAT5low (OS, 44.8% vs. 65.2%, p = 0.004; EFS, 23.5% vs. 52.1%, p < 0.001), which was further confirmed in an external validation cohort. Furthermore, pSTAT5 plus flow-based minimal residual disease (MRD) postinduction defines a novel risk classification as being high risk (HR, pSTAT5high + MRD+), standard risk (SR, pSTAT5low + MRD-) and others as moderate-risk group. Three identified patient subgroups are distinguishable with disparate survival curves (3-year OS rates, 36.5%, 56.7% and 76.3%, p < 0.001), which was confirmed on multivariate analysis (hazard ratio 3.53, p = 0.003). Collectively, our study proposed a novel, simple and flow-based risk classification by integrating pSTAT5 and MRD in favour of risk-guided treatment for B-ALL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Xu X, Huang Z, Ding C, et al. STAT5 phosphorylation plus minimal residual disease defines a novel risk classification in adult B-cell acute lymphoblastic leukaemia. Br J Haematol. 2024. PMID: 38639167. doi:10.1111/bjh.19467

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。